News Release

February 28, 2012

Contact: Geoffrey Schwartz Phone: +1 951-514-4223 Email: geoffrey.schwartz@merckgroup.com

EMD Millipore Launches MILLIPLEX® MAP EpiQuant™ Receptor Signaling Pathway Panel

• Luminex®-based approach for profiling total and phosphorylated receptor tyrosine kinases, non-receptor tyrosine kinases, cellular kinases and a phosphotase
• Measure phosphorylation site-specific concentrations of proteins and multiple phosphorylation sites on the same protein in the same assay well
• Simultaneously measure total and phosphoprotein

February 28, 2012, Billerica, MA — EMD Millipore, the Life Science division of Merck KGaA* of Darmstadt, Germany, today launched a MILLIPLEX® MAP panel for assessing the functional states of cells by profiling a range of receptor signaling pathway proteins. The Luminex®-based approach enables the profiling of 26 analytes including total and phosphorylated receptor tyrosine kinases, non-receptor tyrosine kinases, cellular kinases, and a phosphotase with picomolar sensitivities. Users can easily design customized panels by selecting only the analytes of interest.

Site-specific, quantitative measurements with picomolar sensitivity support diverse sample types and many research and drug discovery applications. Compared to traditional detection techniques such as western blots, mass spectrometry analyses, and radioactive phosphorylation assays, the EpiQuant™ Receptor Signaling Pathway panel provides faster results, increased assay throughput and specificity.

“The new MILLIPLEX® MAP EpiQuant™ Receptor Signaling Pathway panel overcomes a number of challenges presented by conventional multiplex approaches,” describes Linda Meeh, Ph.D., Director of Marketing for Immunoassays and Multiplexing. “In these approaches, the requirement for native protein conformation can result in complex buffer interactions with phosphoproteins and inter-antibody effects. The EpiQuant™ technology uses antibodies against defined protein sequences to capture peptides resulting from protein linearization and digestion in a single cell lysate sample. This approach enables researchers to measure phosphorylation levels of multiple sites, as well as total protein, simultaneously with absolute quantitation.”

The new panel provides highly validated and characterized immunoassay antibodies, all necessary reagents, and optimized protocols.

For more information, please visit www.millipore.com/bmia.

About EMD Millipore
EMD Millipore is the Life Science division of Merck KGaA of Germany and offers a broad range of innovative, performance products, services and business relationships that enable our customers' success in research, development and production of biotech and pharmaceutical drug therapies. Through dedicated collaboration on new scientific and engineering insights, and as one of the top three R&D investors in the Life Science Tools industry, EMD Millipore serves as a strategic partner to customers and helps advance the promise of life science.

Headquartered in Billerica, Massachusetts, the division has around 10,000 employees, operations in 67 countries an 2010 revenues of $2.2 billion. EMD Millipore is known as Merck Millipore outside of the U.S. and Canada.

Note: Merck KGaA or Merck shall mean Merck KGaA, Darmstadt, Germany